- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01285609
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Cape Town, Afrique du Sud, 7925
- Local Institution
-
Durban, Afrique du Sud, 4067
- Local Institution
-
-
Gauteng
-
Vereeniging, Gauteng, Afrique du Sud, 1939
- Local Institution
-
-
Western CAPE
-
Panorama,cape Town, Western CAPE, Afrique du Sud, 7500
- Local Institution
-
-
-
-
-
Bad Berka, Allemagne, 99437
- Local Institution
-
Bochum, Allemagne, 44791
- Local Institution
-
Darmstadt, Allemagne, 64283
- Local Institution
-
Dresden, Allemagne, 01307
- Local Institution
-
Frankfurt Am Main, Allemagne, 60590
- Local Institution
-
Gauting, Allemagne, 82131
- Local Institution
-
Grosshandsdorf, Allemagne, 22927
- Local Institution
-
Hamburg, Allemagne, D-21075
- Local Institution
-
Heidelberg, Allemagne, 69126
- Local Institution
-
Kassel, Allemagne, 34125
- Local Institution
-
Lubeck, Allemagne, 23538
- Local Institution
-
Mainz, Allemagne, 55131
- Local Institution
-
Muenchen, Allemagne, 81925
- Local Institution
-
Neumunster, Allemagne, 24534
- Local Institution
-
Nuernberg, Allemagne, 90419
- Local Institution
-
Regensburg, Allemagne, 93049
- Local Institution
-
Tuebingen, Allemagne, 72076
- Local Institution
-
Ulm, Allemagne, 89081
- Local Institution
-
Villingen-Schwenningen, Allemagne, 78052
- Local Institution
-
-
-
-
-
Cordoba, Argentine, X5006HBF
- Local Institution
-
Cordoba, Argentine, X5006IKK
- Local Institution
-
Mendoza, Argentine, M5500AYB
- Local Institution
-
Santa Fe, Argentine, S3000FFU
- Local Institution
-
-
Buenos Aires
-
Quilmes, Buenos Aires, Argentine, B1878DVB
- Local Institution
-
-
Santa FE
-
Rosario, Santa FE, Argentine, S2000DSV
- Local Institution
-
-
Tucuman
-
San Miguel De Tucuman, Tucuman, Argentine, 4000
- Local Institution
-
-
-
-
South Australia
-
Bedford Park, South Australia, Australie, 5042
- Local Institution
-
-
Victoria
-
Box Hill, Victoria, Australie, 3128
- Local Institution
-
Frankston, Victoria, Australie, 3199
- Local Institution
-
Heidelberg, Victoria, Australie, 3084
- Local Institution
-
Wodonga, Victoria, Australie, 3690
- Local Institution
-
-
-
-
-
Aalst, Belgique, 9300
- Local Institution
-
Liege, Belgique, 4000
- Local Institution
-
Sint Niklaas, Belgique, 9100
- Local Institution
-
Yvoir, Belgique, 5530
- Local Institution
-
-
-
-
-
Porto Alegre, Brésil, 90430
- Local Institution
-
Ribeirao Preto, Brésil, 14015
- Local Institution
-
Rio de Janeiro, Brésil, 20231-050
- Local Institution
-
Sao Paulo, Brésil, 01224-010
- Local Institution
-
Sao Paulo, Brésil, 04039-901
- Local Institution
-
-
Ceara
-
Fortaleza, Ceara, Brésil, 60160-230
- Local Institution
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brésil, 30150-270
- Local Institution
-
-
Parana
-
Curitiba, Parana, Brésil, 81520-060
- Local Institution
-
-
RIO Grande DO SUL
-
Passo Fundo, RIO Grande DO SUL, Brésil, 99010260
- Local Institution
-
-
SAO Paulo
-
Barretos, SAO Paulo, Brésil, 14784
- Local Institution
-
Sao Jose dos Campos, SAO Paulo, Brésil, 12245
- Local Institution
-
-
-
-
-
Oshawa, Canada, L1G 2B9
- Local Institution
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- Local Institution
-
Montreal, Quebec, Canada, H3T 1E2
- Local Institution
-
Montreal, Quebec, Canada, H4J 1C5
- Local Institution
-
-
-
-
Metropolitana
-
Santiago, Metropolitana, Chili, 7520378
- Local Institution
-
Santiago, Metropolitana, Chili, 8380455
- Local Institution
-
-
Valparaiso
-
Vina Del Mar, Valparaiso, Chili, 2540364
- Local Institution
-
-
-
-
-
Beijing, Chine, 100032
- Local Institution
-
Beijing, Chine, 100071
- Local Institution
-
Beijing, Chine, 100142
- Local Institution
-
Beijing, Chine, 100853
- Local Institution
-
Santiago, Chine, 7630370
- Local Institution
-
Shanghai, Chine, 200030
- Local Institution
-
Shanghai, Chine, 200433
- Local Institution
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510060
- Local Institution
-
Guanzhou, Guangdong, Chine, 510080
- Local Institution
-
Shantou, Guangdong, Chine, 515041
- Local Institution
-
-
Hubei
-
Wuhan, Hubei, Chine, 430023
- Local Institution
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210002
- Local Institution
-
Nanjing, Jiangsu, Chine, 210009
- Local Institution
-
Suzhou, Jiangsu, Chine, 215006
- Local Institution
-
-
Jilin
-
Changchun, Jilin, Chine, 130012
- Local Institution
-
-
Shaanxi
-
Xi'an, Shaanxi, Chine, 710038
- Local Institution
-
Xi'an, Shaanxi, Chine, 710061
- Local Institution
-
-
Xinjiang
-
Urumqi, Xinjiang, Chine, 830011
- Local Institution
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310016
- Local Institution
-
-
-
-
Cordoba
-
Monteria, Cordoba, Colombie
- Local Institution
-
-
Risaralda
-
Pereira, Risaralda, Colombie
- Local Institution
-
-
-
-
-
Busan, Corée, République de, 602-739
- Local Institution
-
Daegu, Corée, République de, 700-712
- Local Institution
-
Gyeonggi-do, Corée, République de, 463-802
- Local Institution
-
Seoul, Corée, République de, 110-744
- Local Institution
-
Seoul, Corée, République de, 138-736
- Local Institution
-
Seoul, Corée, République de, 134-791
- Local Institution
-
Seoul, Corée, République de, 135-720
- Local Institution
-
Seoul, Corée, République de, 136-705
- Local Institution
-
Seoul, Corée, République de, 137-701
- Local Institution
-
Seoul, Corée, République de, 156-755
- Local Institution
-
Suwon, Corée, République de, 443-721
- Local Institution
-
-
Chungcheongbuk-do
-
Cheonju-si, Chungcheongbuk-do, Corée, République de, 361-771
- Local Institution
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Corée, République de, 410-769
- Local Institution
-
Suwon-si, Gyeonggi-do, Corée, République de, 442-723
- Local Institution
-
-
Kangnam-gu
-
Seoul, Kangnam-gu, Corée, République de, 135-710
- Local Institution
-
-
Seodaemungu
-
Seoul, Seodaemungu, Corée, République de, 120-752
- Local Institution
-
-
-
-
-
Aalborg, Danemark, 9000
- Local Institution
-
Herlev, Danemark, 2730
- Local Institution
-
Hillerod, Danemark, 3400
- Local Institution
-
Naestved, Danemark, 4700
- Local Institution
-
Odense, Danemark, 5000
- Local Institution
-
-
-
-
-
Avila, Espagne, 05004
- Local Institution
-
Benidorm-alicante, Espagne, 03501
- Local Institution
-
Castellon, Espagne, 12002
- Local Institution
-
Madrid, Espagne, 28041
- Local Institution
-
Madrid, Espagne, 28033
- Local Institution
-
Manresa, Espagne, 08243
- Local Institution
-
Ourense, Espagne, 32005
- Local Institution
-
Valencia, Espagne, 46014
- Local Institution
-
Valencia, Espagne, 46015
- Local Institution
-
-
Vizcaya
-
Barakaldo, Vizcaya, Espagne, 48903
- Local Institution
-
-
-
-
-
Caen Cedex 05, France, 14076
- Local Institution
-
Marseille Cedex 20, France, 13915
- Local Institution
-
Paris, France, 75014
- Local Institution
-
Poitiers, France, 86000
- Local Institution
-
Rennes Cedex 9, France, 35033
- Local Institution
-
Toulouse Cedex 9, France, 31059
- Local Institution
-
Vandoeuvre-les-nancy, France, 54511
- Local Institution
-
-
-
-
-
Chelyabinsk, Fédération Russe, 454087
- Local Institution
-
Kazan, Fédération Russe, 420029
- Local Institution
-
Moscow, Fédération Russe, 115478
- Local Institution
-
Moscow, Fédération Russe, 125009
- Local Institution
-
Pyatigorsk, Fédération Russe, 357502
- Local Institution
-
Saint Petersburg, Fédération Russe, 197758
- Local Institution
-
St-Peterburg, Fédération Russe, 198255
- Local Institution
-
St. Petersburg, Fédération Russe, 197022
- Local Institution
-
Tula, Fédération Russe, 300053
- Local Institution
-
-
-
-
-
Hong Kong, Hong Kong, 8525
- Local Institution
-
Hong Kong, Hong Kong
- Local Institution
-
New Territories, Hong Kong, 8520
- Local Institution
-
-
-
-
-
Budapest, Hongrie, 1121
- Local Institution
-
Budapest, Hongrie, 1125
- Local Institution
-
Deszk, Hongrie, 6772
- Local Institution
-
Farkasgyepu, Hongrie, 8582
- Local Institution
-
Gyula, Hongrie, 5703
- Local Institution
-
Matrahaza, Hongrie, 3233
- Local Institution
-
Nyiregyhaza, Hongrie, 4400
- Local Institution
-
Pecs, Hongrie, 7602
- Local Institution
-
Sopron, Hongrie, 9400
- Local Institution
-
Szekesfehervar, Hongrie, 8000
- Local Institution
-
Szolnok, Hongrie, 5000
- Local Institution
-
-
-
-
-
Dublin, Irlande, 24
- Local Institution
-
Dublin, Irlande, 4
- Local Institution
-
Dublin, Irlande, 8
- Local Institution
-
Galway, Irlande
- Local Institution
-
-
-
-
-
Beer Sheva, Israël, 84101
- Local Institution
-
Haifa, Israël, 31096
- Local Institution
-
Jerusalem, Israël, 91120
- Local Institution
-
Nahariya, Israël, 22100
- Local Institution
-
Petah-Tikva, Israël, 49100
- Local Institution
-
Rehovot, Israël, 76100
- Local Institution
-
Tel Aviv, Israël, 64239
- Local Institution
-
Tel-aviv, Israël, 69710
- Local Institution
-
Tel-hashomer, Israël, 52621
- Local Institution
-
Zerifin, Israël, 70300
- Local Institution
-
-
-
-
-
Benevento, Italie, 82100
- Local Institution
-
Bologna, Italie, 40138
- Local Institution
-
Lido Di Camaiore, Italie, 55041
- Local Institution
-
Lucca, Italie, 55100
- Local Institution
-
Monza, Italie, 20052
- Local Institution
-
Padova, Italie, 35128
- Local Institution
-
Perugia, Italie, 06156
- Local Institution
-
Siena, Italie, 53100
- Local Institution
-
Sondrio, Italie, 23100
- Local Institution
-
Terni, Italie, 05100
- Local Institution
-
Treviglio, Italie, 24047
- Local Institution
-
-
-
-
-
Akashi, Hyogo, Japon, 6738558
- Local Institution
-
Fukuoka, Japon, 8128582
- Local Institution
-
Matsuyama, Ehime, Japon, 791-0280
- Local Institution
-
Osakasayama-city, Japon, 5898511
- Local Institution
-
Sapporo Hokkaido, Japon, 003-080
- Local Institution
-
Sapporo, Hokkaido, Japon, 0608648
- Local Institution
-
Sendai, Miyagi, Japon, 980-0873
- Local Institution
-
Takatsuki, Japon, 569-8686
- Local Institution
-
Tokyo, Japon, 135-8550
- Local Institution
-
-
Aichi
-
Nagoya, Aichi, Japon, 4648681
- Local Institution
-
Nagoya-shi, Aichi, Japon, 4600001
- Local Institution
-
-
Chiba
-
Kashiwa, Chiba, Japon, 277-8577
- Local Institution
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japon, 9208641
- Local Institution
-
-
Kanagawa
-
Yokohama-Shi, Kanagawa, Japon, 2360051
- Local Institution
-
Yokohama-shi, Kanagawa, Japon, 2408555
- Local Institution
-
-
Miyagi
-
Natori-shi, Miyagi, Japon, 9811293
- Local Institution
-
Sendai, Miyagi, Japon, 9808574
- Local Institution
-
-
Okayama
-
Kurashiki-shi, Okayama, Japon, 7010192
- Local Institution
-
Kurashiki-shi, Okayama, Japon, 710-8602
- Local Institution
-
-
Osaka
-
Hirakata-shi, Osaka, Japon, 5731191
- Local Institution
-
Osaka-shi, Osaka, Japon, 5340021
- Local Institution
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japon, 411-8777
- Local Institution
-
-
Tokyo
-
Chuo-ku, Tokyo, Japon, 104-0045
- Local Institution
-
-
Yamaguchi
-
Ube-shi, Yamaguchi, Japon, 7550241
- Local Institution
-
-
-
-
-
Graz, L'Autriche, 8036
- Local Institution
-
Linz, L'Autriche, 4020
- Local Institution
-
Salzburg, L'Autriche, 5020
- Local Institution
-
-
-
-
-
Lisboa, Le Portugal, 1099023
- Local Institution
-
Lisboa, Le Portugal, 1769-001
- Local Institution
-
Porto, Le Portugal, 4200-072
- Local Institution
-
Santa Maria Da Feira, Le Portugal, 4520211
- Local Institution
-
Vila Nova De Gaia, Le Portugal, 4434-502
- Local Institution
-
-
Coimbra
-
Sao Martinho Do Bispo, Coimbra, Le Portugal, 3041801
- Local Institution
-
-
-
-
Distrito Federal
-
Mexico, Distrito Federal, Mexique, 06760
- Local Institution
-
-
Jalisco
-
Zapopan, Jalisco, Mexique, 45170
- Local Institution
-
-
Nuevo LEON
-
Monterrey, Nuevo LEON, Mexique, 64060
- Local Institution
-
-
-
-
-
Breda, Pays-Bas, 4818 CK
- Local Institution
-
Harderwijk, Pays-Bas, 3844 DG
- Local Institution
-
Hertogenbosch, Pays-Bas, 5223 GZ
- Local Institution
-
Nieuwegein, Pays-Bas, 3435 CM
- Local Institution
-
-
-
-
-
Elblag, Pologne, 82-300
- Local Institution
-
Gdansk, Pologne, 80-952
- Local Institution
-
Gdansk- Zaspa, Pologne, 80-462
- Local Institution
-
Grudziadz, Pologne, 86-300
- Local Institution
-
Olsztyn, Pologne, 10-357
- Local Institution
-
Otwock, Pologne, 05-400
- Local Institution
-
Poznan, Pologne, 60 569
- Local Institution
-
Szczecin, Pologne, 70-891
- Local Institution
-
Torun, Pologne, 87-100
- Local Institution
-
Warsaw, Pologne, 02-781
- Local Institution
-
-
-
-
-
Arequipa, Pérou
- Local Institution
-
Cercado, Pérou
- Local Institution
-
Lima, Pérou, LIMA 11
- Local Institution
-
-
LA Libertad
-
Trujillo, LA Libertad, Pérou
- Local Institution
-
-
-
-
-
Bucharest, Roumanie, 030171
- Local Institution
-
Bucuresti, Roumanie, 010976
- Local Institution
-
Cluj Napoca, Roumanie, 400058
- Local Institution
-
Sibiu, Roumanie, 550245
- Local Institution
-
Suceava, Roumanie, 720237
- Local Institution
-
Timisoara, Roumanie, 300239
- Local Institution
-
-
-
-
-
Nottingham, Royaume-Uni, NG51PB
- Local Institution
-
Sheffield, Royaume-Uni, S10 2SJ
- Local Institution
-
-
Angus/forfarshire
-
Dundee, Angus/forfarshire, Royaume-Uni, DD1 9SY
- Local Institution
-
-
Cornwall
-
Truro, Cornwall, Royaume-Uni, TR1 3LJ
- Local Institution
-
-
Hampshire
-
Southampton, Hampshire, Royaume-Uni, SO16 6YD
- Local Institution
-
-
-
-
-
Singapore, Singapour, 308433
- Local Institution
-
-
-
-
-
Basel, Suisse, 4031
- Local Institution
-
Winterthur, Suisse, 8401
- Local Institution
-
-
-
-
-
Gothenburg, Suède, 413 45
- Local Institution
-
Lund, Suède, 221 85
- Local Institution
-
Stockholm, Suède, 17176
- Local Institution
-
Umea, Suède, SE-901 85
- Local Institution
-
-
-
-
-
Changhua City, Taïwan, 500
- Local Institution
-
Chiayi, Taïwan, 61363
- Local Institution
-
Kaohsiung County, Taïwan, 83301
- Local Institution
-
Taichung, Taïwan, 404
- Local Institution
-
Taichung, Taïwan, 407.5
- Local Institution
-
Taipei, Taïwan, 112
- Local Institution
-
Taipei, Taïwan
- Local Institution
-
Taipei City, Taïwan, 100
- Local Institution
-
-
-
-
-
Prague 2, Tchéquie, 12808
- Local Institution
-
Praha 5, Tchéquie, 150 06
- Local Institution
-
Praha 8, Tchéquie, 180 81
- Local Institution
-
Pribram V-Zdabor, Tchéquie, 26195
- Local Institution
-
Usti Nad Labem, Tchéquie, 401 13
- Local Institution
-
Znojmo, Tchéquie, 669 02
- Local Institution
-
-
Poruba
-
Ostrava, Poruba, Tchéquie, 70852
- Local Institution
-
-
-
-
-
Bangkok, Thaïlande, 10400
- Local Institution
-
Bangkok, Thaïlande, 10700
- Local Institution
-
Bangkok, Thaïlande, 10330
- Local Institution
-
Chiang Mai, Thaïlande, 50200
- Local Institution
-
Songkhla, Thaïlande, 90110
- Local Institution
-
-
Tungpayathai
-
Bangkok, Tungpayathai, Thaïlande, 10400
- Local Institution
-
-
-
-
California
-
San Diego, California, États-Unis, 92123
- Sharp Memorial Hospital
-
-
Connecticut
-
West Haven, Connecticut, États-Unis, 06516
- VA Connecticut Healthcare System
-
-
Florida
-
Boca Raton, Florida, États-Unis, 33486
- Lynn Cancer Institute Center For Hematology-Oncology
-
Jacksonville, Florida, États-Unis, 32256
- Integrated Community Oncology Network
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- University of Illinois at Chicago Medical Center
-
Quincy, Illinois, États-Unis, 62301
- Quincy Medical Group
-
Skokie, Illinois, États-Unis, 60076
- Presence Medical Group Hematology Oncology
-
Springfield, Illinois, États-Unis, 62794-9678
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46237
- St. Francis Hospital & Health Centers
-
New Albany, Indiana, États-Unis, 47150
- Floyd Memorial Cancer Center of Indiana
-
-
Kentucky
-
Hazard, Kentucky, États-Unis, 41701
- Kentucky Cancer Clinic
-
Louisville, Kentucky, États-Unis, 40207
- Norton Cancer Institute
-
Mount Sterling, Kentucky, États-Unis, 40353
- Montgomery Cancer Center
-
-
Michigan
-
Ypsilanti, Michigan, États-Unis, 48197
- St Joseph Mercy Hospital
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64131
- University of Kansas Cancer Center
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756-0001
- Dartmouth-Hitchcock Medical Center
-
-
New York
-
Lake Success, New York, États-Unis, 11042
- Clinical Research Alliance, Inc.
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27705
- Durham Va Medical Center (111g)
-
Huntersville, North Carolina, États-Unis, 28078
- Carolina BioOncology Institute
-
Lexington, North Carolina, États-Unis, 27295
- Novant Health Oncology Specialists
-
-
Ohio
-
Canton, Ohio, États-Unis, 44718
- Gabrail Cancer Center Research
-
-
Oklahoma
-
Tulsa, Oklahoma, États-Unis, 74146
- Oklahoma Oncology And Hematology, Pc Dba
-
-
Oregon
-
Portland, Oregon, États-Unis, 97227
- Kaiser Permanente Northwest Region
-
-
Pennsylvania
-
Sayre, Pennsylvania, États-Unis, 18840
- Guthrie Medical Group, P.C.
-
-
South Carolina
-
Columbia, South Carolina, États-Unis, 29209
- WJB Dorn VA Medical Center
-
Greenville, South Carolina, États-Unis, 29615
- Cancer Center Of The Carolinas
-
-
Tennessee
-
Chattanooga, Tennessee, États-Unis, 37421
- Associated in Oncology and Hematology
-
Knoxville, Tennessee, États-Unis, 37909
- Tennessee Cancer Specialists
-
Knoxville, Tennessee, États-Unis, 37916
- Thompson Oncology Group
-
-
Texas
-
Austin, Texas, États-Unis, 78745
- Texas Oncology, PA - South Austin Cancer Center
-
-
Virginia
-
Blacksburg, Virginia, États-Unis, 24060
- Blue Ridge Cancer Care
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53705
- Wisconsin Institutes for Medical Research
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
- Non small cell lung cancer (NSCLC) - squamous cell
- Stage IV or recurrent NSCLC
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
- Brain Metastases
- Autoimmune diseases
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Ipilimumab + Paclitaxel and Carboplatin
Ipilimumab + Active Chemo Backbone Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose) Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses |
Autres noms:
Autres noms:
Autres noms:
|
Comparateur placebo: Placebo + Paclitaxel and Carboplatin
Placebo + Active Chemo Backbone Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose) Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses |
Autres noms:
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint
Délai: Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
|
Overall Survival (OS) was defined as the time from randomization to the date of death.
Participants that had not died were censored at last known date alive.
Median OS time was calculated using Kaplan-Meier Estimates.
Analysis for the Primary Endpoint occurred when the following 2 conditions were both met: (1) 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and (2) 705 deaths were observed in all randomized participants.
|
Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Overall Survival (OS) in All Randomized Participants at Primary Endpoint
Délai: Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
|
Overall Survival (OS) was defined as the time from randomization to the date of death.
Participants that had not died were censored at last known date alive.
Median OS time was calculated using Kaplan-Meier Estimates.
Analysis for the Primary Endpoint occurred when the following 2 conditions were both met: (1) 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and (2) 705 deaths were observed in all randomized participants.
|
Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
|
Median Number of Months With Progression Free Survival (PFS) Per mWHO in Participants Who Have Received at Least One Dose of Blinded Study Therapy at Primary Endpoint
Délai: Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
|
Progression-free survival (PFS) is defined as the time between the date of randomization and the date of tumor progression per Modified World Health Organization (mWHO) criteria or death, whichever occurs first.
A participant who died without reported progression per mWHO criteria were considered to have progressed on the date of death.
For participants who remain alive and have not progressed, PFS was censored on the date of last evaluable tumor assessment.
For participants who remain alive and have no recorded post-baseline tumor assessment, PFS was censored on the day of randomization.
|
Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Tumeurs
- Maladies pulmonaires
- Tumeurs par site
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Mécanismes moléculaires de l'action pharmacologique
- Agents antinéoplasiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Agents antinéoplasiques phytogéniques
- Agents antinéoplasiques immunologiques
- Inhibiteurs de point de contrôle immunitaire
- Carboplatine
- Paclitaxel
- Ipilimumab
Autres numéros d'identification d'étude
- CA184-104
- 2009-017396-19 (Numéro EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Complété
-
Regado Biosciences, Inc.ComplétéVolontaire en bonne santéÉtats-Unis